-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Sanofi and Regeneron jointly announced that the US FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of PD-L1 high expression (tumor ratio score ≥50%) Patients with advanced non-small cell lung cancer (NSCLC).
Whether in the world or in China, lung cancer is the leading cause of cancer deaths.
Libtayo is a fully humanized monoclonal antibody that targets the immune checkpoint receptor PD-1 on the surface of T cells.
Data from a phase 3 clinical trial recently published in The Lancet showed that Libtayo reduced the risk of death by 43% compared with chemotherapy in patients whose tumor PD-L1 expression was ≥50% confirmed by the FDA-approved test.
"Libtayo is approved for the treatment of first-line advanced non-small cell lung cancer with high PD-L1 expression, adding a powerful new treatment option for doctors and patients.
Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.
Reference materials:
[1] FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%.
